New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
14:53 EDTARRYArray BioPharma to present positive Phase 2 data on ARRY-797
Array BioPharma announced that an abstract discussing the final Phase 2 trial results with ARRY-797 in patients with osteoarthritis pain will be presented at the 2012 American College of Rheumatology Annual Meeting in Washington, D.C. This abstract includes data on ARRY-797's analgesic effect and markers of disease modification. In addition, biomarkers of cartilage (COMP) and bone (CTX I) degradation were assessed. ARRY 797 treatment resulted in statistically significant decreases in COMP and CTX I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX I was sustained and returned to baseline by the follow up visit. The abstract concludes that further evaluation of the potential for disease modifying activity is warranted.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
10:11 EDTARRYOptions with decreasing implied volatility
Subscribe for More Information
June 23, 2015
10:30 EDTARRYOptions with decreasing implied volatility
Subscribe for More Information
June 19, 2015
05:55 EDTARRYPiper sees 'transformative' two years for Array BioPharma
Piper Jaffray analyst Edward Tenthoff expects the next two years to be "transformative" for Array BioPharma (ARRY), with the company reporting pivotal data and likely gaining approval on wholly-owned MEK inhibitor binimetinib and BRAF inhibitor encorafenib. In addition, partner AstraZeneca (AZN) will report selumetinib data in uveal melanoma and file a new drug application this year resulting in royalty revenue to Array in 2016, the analyst tells investors today in a research note. Tenthoff reiterates an Overweight rating on the stock with a $15 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use